According to the latest report by IMARC Group, titled “Multiple Myeloma Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global multiple myeloma drugs market grew at a CAGR of around 9% during 2014-2019. Multiple myeloma, or Kahler’s disease, refers to a form of cancer that is formed in the plasma cells. It causes cancer cells to produce abnormal proteins that accumulate in the bone marrow and destroy the healthy blood cells. Some of the most widely used myeloma drugs include corticosteroids and immunomodulatory and chemotherapeutic agents. These drugs help in healing bones and preventing bone fractures, spinal cord compressions, anemia, and hypercalcemia.
Request Free Sample Report: https://www.imarcgroup.com/multiple-myeloma-drugs-market/requestsample
Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves targeted drug therapies, like the proteasome inhibitor that includes bortezomib and other compounds. Other than this, radiological procedures are also a preferred treatment option during the later phase for pain management caused due to bone deterioration. The rising awareness regarding the benefits of these treatment drugs and procedures has led to their escalated demand. Apart from this, the increasing healthcare expenditure and the extensive research and development (R&D) activities funded by the government and private institutions to develop microRNA therapeutics and nanomedicines for the treatment of multiple myeloma are expected to create a positive outlook for the market in the coming years. Looking forward, IMARC Group expects the multiple myeloma drugs market to witness moderate growth during the next five years.
Breakup by Therapy:
- Targeted Therapy
- Biologic Therapy
Breakup by Drug Type:
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
Breakup by End-User:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Competitive Landscape Key Player:
- Amgen Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Genzyme Corporation (Sanofi-Aventis)
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Pharma Mar S.A.
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceutical Industries Ltd.
Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://bit.ly/3eFJ0KW
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Single User: https://www.imarcgroup.com/checkout?id=2169&method=1
Corporate User: https://www.imarcgroup.com/checkout?id=2169&method=3
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800